(Reuters) – The revenues and benefit of Johnson & Johnson (J & J) in the first quarter exceeded the expectations on Tuesday, brought by sales of its anti -cancer treatments, including Darzalex against multiple myeloma.

I also noted its annual sales forecasts, while lowering its profit prospects, in order to reflect the impact of customs duties imposed by the Trump administration and the dilution of its $ 14.6 billion agreement (12.88 billion euros) for the repurchase of the manufacturer of intra-cellular neurological drugs.

The group is now expecting sales from 91.6 to 92.4 billion dollars, compared to $ 90.9 to $ 91.7 billion previously due to the purchase of Caplyta, the main medication of intra-cellular against schizophrenia.

J & J plans to gain between $ 10.50 and $ 10.70 per share on an adjusted basis, against a previous forecast of 10.75 to 10.95 dollars.

Financial director Joe Wolk said during an interview that the adjustment of the profit takes into account the impact of around $ 400 million expected in the medical technology segment of J & J, due to the customs duties currently in force, including those imposed on China and Mexico.

“This is more an event in the second quarter (and) to come (…) which covers all the programs in place today, even if they have been paused,” he said.

The New Jersey-based pharmaceutical company recorded a turnover of $ 21.89 billion for the first three months of the year, up 2.4% over a year and above analysts’ expectations, which were tabling on $ 21.56 billion, according to LSEG data.

On an adjusted basis, the group won $ 2.77 per share during the quarter, 2.2% more than the previous year and above the $ 2.59 per share expected by analysts.

Joe Wolk said the group still expected, as indicated in its January forecasts, that its medical technology activities are more efficient during the second half of the year.

(Written by Bhanvi Satija in Bangalore and Patrick Wingrove in New York; edited by Augustin Turpin)

Copyright © 2025 Thomson Reuters